Summary of Significant Accounting Policies - Additional Information (Details) (USD $)
In Thousands, except Share data, unless otherwise specified |
0 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | 0 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 11, 2013
|
Sep. 30, 2014
|
Sep. 30, 2013
|
Sep. 30, 2014
Segment
Product
|
Sep. 30, 2013
|
Mar. 07, 2014
|
Feb. 20, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Sep. 30, 2014
Common Stock
|
Feb. 20, 2014
Inogen, Inc.
|
Feb. 20, 2014
Stockholders
|
Sep. 30, 2014
Accounts Receivable
|
Dec. 31, 2013
Accounts Receivable
|
Sep. 30, 2014
Customer Concentration Risk
Medicare Service Reimbursement Programs
Compared to Rental Revenue
|
Sep. 30, 2013
Customer Concentration Risk
Medicare Service Reimbursement Programs
Compared to Rental Revenue
|
Sep. 30, 2014
Customer Concentration Risk
Medicare Service Reimbursement Programs
Compared to Rental Revenue
|
Sep. 30, 2013
Customer Concentration Risk
Medicare Service Reimbursement Programs
Compared to Rental Revenue
|
Sep. 30, 2014
Customer Concentration Risk
Medicare Service Reimbursement Programs
Compared to Total Revenue
|
Sep. 30, 2013
Customer Concentration Risk
Medicare Service Reimbursement Programs
Compared to Total Revenue
|
Sep. 30, 2014
Customer Concentration Risk
Medicare Service Reimbursement Programs
Compared to Total Revenue
|
Sep. 30, 2013
Customer Concentration Risk
Medicare Service Reimbursement Programs
Compared to Total Revenue
|
Sep. 30, 2014
Credit Concentration Risk
Medicare Service Reimbursement Programs
Compared to Total Accounts Receivable
|
Dec. 31, 2013
Credit Concentration Risk
Medicare Service Reimbursement Programs
Compared to Total Accounts Receivable
|
Sep. 30, 2014
vendor one
raw materials
|
Sep. 30, 2013
vendor one
raw materials
|
Sep. 30, 2014
vendor one
Vendor Two
|
Sep. 30, 2013
vendor one
Vendor Two
|
Sep. 30, 2014
vendor one
Vendor Three
|
Sep. 30, 2013
vendor one
Vendor Three
|
Sep. 30, 2014
Maximum
Customer Concentration Risk
Total revenue
Single Customer
|
Sep. 30, 2013
Maximum
Customer Concentration Risk
Total revenue
Single Customer
|
Sep. 30, 2014
Service Contracts
|
|
Significant Accounting Policies [Line Items] | |||||||||||||||||||||||||||||||||
Extended service contracts | Lifetime of the patient | 12 to 24 months | |||||||||||||||||||||||||||||||
Accrual of product warranty liability | $ 1,172 | $ 1,172 | $ 809 | $ 447 | |||||||||||||||||||||||||||||
Number of deliverables qualifying as separate units | 2 | ||||||||||||||||||||||||||||||||
Deliverable standard warranty, period | 3 years | ||||||||||||||||||||||||||||||||
Estimation for sale of products | The Company estimates that 60% of patients will succumb to their disease within three years. Given the approximate mortality rate of 20% per year, the Company estimates on average all patients will succumb to their disease within five years. | ||||||||||||||||||||||||||||||||
Rental revenue earned | 30-day period | ||||||||||||||||||||||||||||||||
Unbilled Receivables | 3,410 | 3,410 | 1,435 | ||||||||||||||||||||||||||||||
Concentration risk, percentage | 78.60% | 70.80% | 74.30% | 73.10% | 26.70% | 27.40% | 25.60% | 28.80% | 20.30% | 25.00% | 18.80% | 15.70% | 17.80% | 14.90% | 8.00% | 8.60% | 10.00% | 10.00% | |||||||||||||||
Accounts Receivable Net Current | 18,061 | 18,061 | 10,231 | 3,661 | 2,560 | ||||||||||||||||||||||||||||
Cost Of Property Repairs And Maintenance | 367 | 251 | 1,157 | 707 | |||||||||||||||||||||||||||||
Property Plant And Equipment Salvage Value | $ 0 | $ 0 | |||||||||||||||||||||||||||||||
Number Of Operating Segments | 1 | ||||||||||||||||||||||||||||||||
Reverse stock split ratio | 3:1 | ||||||||||||||||||||||||||||||||
Effective date of reverse stock split | Nov. 12, 2013 | ||||||||||||||||||||||||||||||||
Common stock, par value | $ 0.001 | $ 0.001 | $ 16.00 | $ 0.001 | |||||||||||||||||||||||||||||
Common stock, shares issued | 18,436,802 | 18,436,802 | 4,411,763 | 280,974 | |||||||||||||||||||||||||||||
Number of shares sold | 3,529,411 | 882,352 | |||||||||||||||||||||||||||||||
Common stock purchased by underwriters | 99,550 | ||||||||||||||||||||||||||||||||
Conversion of preferred stock, shares | 14,259,647 |